UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes

Diabetes Care

Volumn 21, Issue 1, 1998, Pages 87-92

  Wright, Alex D ^b   Cull, Carole A ^a   Holman, Rury R ^b   Turner, Robert C ^b  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CHLORPROPAMIDE; GLIBENCLAMIDE; HEMOGLOBIN; METFORMIN; SULFONYLUREA; UKPDS 28; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL;

EID: 0031964322     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.1.87     Document Type: Article

References (19)

1. UKPDS Group: U.K. Prospective Diabetes Study 13: relative efficacy of randomly allocated diet, sulfonylurea, insulin, or metformin in patients with newly diagnosed non-insulin-dependent diabetes followed for three years. BMJ 310:83-88, 1995
2. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333: 541-549, 1995
3. Bailey CJ, Turner RC: Metformin. N Engl J Med 334:574-579, 1996
4. Hundal HS, Ramlal T, Reyes R, Leiter LA, Klip A: Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology 131:1165-1173, 1992
5. Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, Ventura MM, Santeusanio F, Brunetti P, Bolli GB: Acute antihyperglycemic mechanisms of metformin in NIDDM. Diabetes, 43:920-928, 1994
6. British Diabetic Association, Royal College of Physicians, Royal College of General Practitioners: Guidelines for good practice in the diagnosis and treatment of non-insulin-dependent diabetes mellitus: report of a joint working party. J R Coll Physicians Lond 27:259-266, 1993
7. American Diabetes Association: Clinical practice recommendations 1995. Diabetes Care 18 (Suppl. 1):1-96, 1995
8. Holman RR, Steemson J, Turner RC: Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement. Diabet Med 4:457-462, 1987
9. University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 1. Design, methods, and baseline results. Diabetes 19:747-783, 1970
10. Clarke BF, Marshall A, McGill RC, MacCuish AC, Duncan LJP: A three-year evaluation of combined sulphonylureametformin treatment in 200 diabetic ketoacidosis-resistant sulphonylurea failures. In Tolbutamide After Ten Years: Excerpta Medica international Congress Series. Vol 149. Butterfield WJH, Westing WV, Eds. New York, Elsevier, 1967, p. 312
11. UKPDS Group: U.K. Prospective Diabetes Study VIII: study design, progress, and performance. Diabetologia 34:877-890, 1991
12. UKPDS Group: U.K. Prospective Diabetes Study 24: Relative efficacy of sulfonylurea, insulin, and metformin therapy in newly diagnosed non-insulin-dependent diabetes with primary diet failure followed for six years. Ann Intern Med. In press
13. UKPDS Group: U.K. Prospective Diabetes Study VI: Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 13:1-11, 1990
14. UKPDS Group: U.K. Prospective Diabetes Study XI: Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11:534-544, 1994
15. SAS Institute: Statistical Analysis System. 6th ed. Cary, NC, SAS Institute, 1990
16. UKPDS Group: U.K. Prospective Diabetes Study 17: A nine-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 124:136-145, 1996
17. Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen-activator inhibitor in NIDDM subjects: a study of two ethnic groups. Diabetes Care 16:621-629, 1993
18. Chan JC, Tomlinson B, Critchley JA, Cockram CS, Walden RJ: Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 16:1035-1038, 1993
19. Stumvoll M, Nurjahan N, Periello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554, 1995